Search results
Results from the WOW.Com Content Network
Here's what lies ahead for Hims & Hers Health stock In the short term, management previously guided for its fourth-quarter 2024 revenue to be within the range of $465 million to $470 million.
The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of December 16, 2024. Travis Hoium has positions in Hims & Hers ...
The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of July 15, 2024. Will Ebiefung has positions in Hims & Hers ...
Hims & Hers Health (NYSE: HIMS) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. Entering trading this week, the stock has fallen by around 15% in value in the past ...
The GLP-1 hype has left the stock. Hims & Hers is a consumer-facing telehealth company that offers medical consultations and prescribes medications and other products for various health-related ...
Growth is set to accelerate starting next quarter, powered by its GLP-1 offering.
In October 2020, Hims closed a deal with Oaktree Capital Management to go public through a blank check company, reaching a valuation of $1.6 billion. [7] As part of the deal, the company was renamed Hims & Hers Health Inc. [11] The transaction was completed in January 2021, and the company started trading publicly on the New York Stock Exchange.
The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of January 6, 2025. Travis Hoium has positions in Hims & Hers ...